RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, September 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 1 news outlet

twitter: 4 X users

Readers on

mendeley: 9 Mendeley

Summary News X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,583 followers.

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma https://t.co/ArAaU5yuQU https://t.co/sBN93HSJB6

25 Sep 2022

Reply Repost Favourite

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma https://t.co/3RyiwW5oE8

16 Sep 2022

Reply Repost Favourite

RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma https://t.co/2TTDLrmh69 https://t.co/vmJSBvcFrH

16 Sep 2022

Reply Repost Favourite

New article: RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma https://t.co/TT9OCpws1w #pancreaticcancer #oncology https://t.co/WgEtQXQw9H

16 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.